AXIM Biotech Begins Phase II Trial For Treatment of IBS With Cannabidiol Chewing Gum

AXIM Biotech Begins Phase II Trial For Treatment of IBS With Cannabidiol Chewing Gum
AXIM Biotech Begins Phase II Trial For Treatment of IBS With Cannabidiol Chewing Gum

Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies Inc. has enrolled 40 patients and commenced its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company's CanChew Plus® CBD gum.

The study is being conducted by Renger Witkamp, Professor and Chair in Nutrition and Pharmacology, at Wageningen University in the Netherlands.

Selected from a pool of over 400 patients, 40 trial patients aged 18-65 will be subject to a randomized, double-blind, cross-over trial of 8 weeks. Patients will receive a maximum 6 chewing gums per day, either containing 50 mg of cannabidiol per chewing gum in case of the CanChew chewing gum, or a placebo chewing gum.
Final data collection for primary outcome measure is estimated to complete in April 2017, with the full study estimated to complete in June 2017.

"Successfully enrolling patients in this IBS clinical trial, which marks the first advancement in cannabinoid research for treatment of IBS in medical history, is an exciting new milestone for AXIM's clinical development program," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "With the global treatment market for IBS estimated to grow in value to $1.5 billion by 2023, AXIM's efforts continue to push forward with cutting-edge solutions to help people suffering from some of the most common gastrointestinal disorders, not only for IBS, but for Irritable Bowel Disease and Ulcerative Colitis as well."

IBS is the most common functional gastrointestinal disorder with a prevalence worldwide ranging from 9-23% and results in around 12% of all physician visits in US. Although the condition is not life-threatening, it strongly impairs quality of life and up to now there is no cure or real treatment for IBS. The objective of the study is to investigate whether the use of a CBD-containing CanChew Plus® chewing gum can contribute to a reduction of IBS symptoms and an improvement of perceived patients' wellbeing.
 

For more information on the trial go to ClinicalTrials.gov